ACAD vs INTR vs NU vs INVA

For growth investors, Inter & Co, Inc.

(INTR) is the stronger pick with 50. 5% revenue growth year-over-year, versus 11. 9% for ACADIA Pharmaceuticals Inc. (ACAD). Innoviva, Inc. (INVA) offers the better valuation at 6. 9x trailing P/E (11. 9x forward), making it the more compelling value choice. Analysts rate ACADIA Pharmaceuticals Inc. (ACAD) a "Buy" — based on 37 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Innoviva, Inc.

(INVA) is the cheapest at 6. 9x versus Nu Holdings Ltd. at 35. 6x. On forward P/E, Inter & Co, Inc. is actually cheaper at 1. 6x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Inter & Co, Inc. wins at 0. 01x versus Innoviva, Inc. 's 1. 15x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Inter & Co, Inc.

(INTR) delivered a total return of +98. 9%, compared to +7. 1% for ACADIA Pharmaceuticals Inc. (ACAD). Over 10 years, the gap is even starker: INTR returned +98. 9% versus ACAD's -22. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Innoviva, Inc.

(INVA) is the lower-risk stock at 0. 13β versus Inter & Co, Inc. 's 1. 39β — meaning INTR is approximately 1006% more volatile than INVA relative to the S&P 500. On balance sheet safety, ACADIA Pharmaceuticals Inc. (ACAD) carries a lower debt/equity ratio of 4% versus 3% for Inter & Co, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Inter & Co, Inc.

(INTR) is pulling ahead at 50. 5% versus 11. 9% for ACADIA Pharmaceuticals Inc. (ACAD). On earnings-per-share growth, the picture is similar: Innoviva, Inc. grew EPS 816. 7% year-over-year, compared to 40. 1% for Inter & Co, Inc.. Over a 3-year CAGR, ACAD leads at 27. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Innoviva, Inc.

(INVA) is the more profitable company, earning 63. 8% net margin versus 8. 8% for Inter & Co, Inc. — meaning it keeps 63. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INVA leads at 38. 5% versus 9. 8% for ACAD. At the gross margin level — before operating expenses — ACAD leads at 91. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Inter & Co, Inc. (INTR) is the more undervalued stock at a PEG of 0. 01x versus Innoviva, Inc. 's 1. 15x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Inter & Co, Inc. (INTR) trades at 1. 6x forward P/E versus 50. 9x for ACADIA Pharmaceuticals Inc. — 49. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for INTR: 79. 1% to $12. 00.

In this comparison, INTR (1.

6% yield) pays a dividend. ACAD, NU, INVA do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Innoviva, Inc.

(INVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 13)). Both have compounded well over 10 years (INVA: +94. 9%, NU: +38. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ACAD (Healthcare) and INTR (Financial Services) and NU (Financial Services) and INVA (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ACAD is a small-cap deep-value stock; INTR is a small-cap high-growth stock; NU is a mid-cap high-growth stock; INVA is a small-cap high-growth stock. INTR pays a dividend while ACAD, NU, INVA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.